文献速递头颈外科

下咽癌治疗延迟的基准与生存关联

Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association.
PubMed 文献 · Otolaryngol Head Neck Surg · 2018-10-16

基于美国国家癌症数据库3850例接受根治性放疗或同步放化疗的下咽癌患者,中位诊断至治疗开始时间37天、放疗持续时间52天、诊断至治疗结束时间92天。放疗期间延迟与总生存受损相关(HR=1.24),而诊断至治疗开始或诊断至治疗结束延迟无此关联;诱导化疗队列中任何延迟均与生存无关。

要点

  • 下咽癌根治性放疗/同步放化疗的中位DTI 37天、RTD 52天、DTE 92天,可作全国基准。
  • 放疗持续时间延迟与总生存受损独立相关(HR=1.24),应优先保障放疗连续性。
  • 医疗补助保险与DTI、RTD、DTE延迟均相关;非白人种族与DTI和DTE延迟相关。

核心结论

  • 下咽癌根治性放疗或同步放化疗患者中,放疗期间延迟与总生存受损相关,而诊断至治疗开始或诊断至治疗结束延迟无此关联。
  • 诱导化疗患者中,DTI、RTD和DTE延迟均与总生存无关。
  • 所报告的中位时间可作为下咽癌治疗延迟的全国基准。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库(Commission on Cancer hospitals nationwide)。
  • 纳入接受根治性放疗、同步放化疗或诱导化疗后放疗的下咽癌患者。
  • 主要分析队列为3850例接受根治性放疗或同步放化疗的患者;另识别922例接受诱导化疗的患者。

主要发现

  • 根治性放疗/同步放化疗队列中位DTI为37天、RTD为52天、DTE为92天。
  • 非白人种族与DTI延迟(OR=0.64;95%CI 0.51-0.80;P<.001)和DTE延迟(OR=0.60;95%CI 0.49-0.75;P<.001)相关。
  • 医疗补助保险与DTI延迟(OR=1.43;95%CI 1.07-1.90;P=.015)、RTD延迟(OR=1.39;95%CI 1.06-1.83;P=.018)和DTE延迟(OR=1.48;95%CI 1.12-1.97;P=.007)相关。
  • RTD延迟与总生存受损相关(HR=1.24;95%CI 1.11-1.37;P<.001),DTI延迟(HR=0.92;95%CI 0.82-1.03;P=.150)和DTE延迟(HR=1.01;95%CI 0.90-1.15;P=.825)与总生存无关。
  • 诱导化疗队列中,DTI、RTD和DTE延迟均与总生存无关(HR=1.10;95%CI 0.87-1.39;P=0.435;HR=1.05;95%CI 0.83-1.32;P=0.686;HR=1.11;95%CI 0.88-1.41;P=0.377)。

关键数值与推荐

  • 根治性放疗或同步放化疗的下咽癌患者中位DTI为37天、RTD为52天、DTE为92天,可作为基准。
  • RTD延迟与总生存受损相关(HR=1.24;95%CI 1.11-1.37;P<.001)。
  • 医疗补助保险与DTI、RTD、DTE延迟相关(OR分别为1.43、1.39、1.48)。
  • 非白人种族与DTI和DTE延迟相关(OR分别为0.64、0.60)。

临床怎么用

  • 可将37天DTI、52天RTD、92天DTE作为下咽癌根治性放疗或同步放化疗的质控基准。
  • 应特别关注放疗持续时间的延迟,因其与总生存受损相关。
  • 对医疗补助保险和非白人患者应加强治疗及时性支持。

局限性

  • 回顾性队列设计,可能存在未测量混杂。
  • 仅纳入国家癌症数据库中有完整治疗信息的患者,存在选择偏倚可能。
  • 诱导化疗队列样本量较小(922例),亚组分析效力有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize treatment delays in hypopharyngeal cancer, identify factors associated with delays, and associate delays with overall survival. STUDY DESIGN: Retrospective cohort. SETTING: Commission on Cancer hospitals nationwide. SUBJECTS AND METHODS: We included patients in the National Cancer Database who were treated for hypopharyngeal cancer with primary radiation, concurrent chemoradiation, or induction chemotherapy and radiation. We identified median durations of diagnosis to treatment initiation (DTI), radiation treatment duration (RTD), and diagnosis to treatment end (DTE). We associated delays with patient, tumor, and treatment factors and overall survival via multivariable logistic and Cox proportional hazards regression, respectively. RESULTS: A total of 3850 patients treated with primary radiation or concurrent chemoradiation were included. Median durations of DTI, RTD, and DTE were 37, 52, and 92 days, respectively. Nonwhite race was associated with delays in DTI (odds ratio [OR] = 0.64; 95% CI, 0.51-0.80; P < .001) and DTE (OR = 0.60; 95% CI, 0.49-0.75; P < .001). Medicaid insurance was associated with delays in DTI (OR = 1.43; 95% CI, 1.07-1.90; P = .015), RTD (OR = 1.39; 95% CI, 1.06-1.83; P = .018), and DTE (OR = 1.48; 95% CI, 1.12-1.97; P = .007). Delays in RTD (hazard ratio [HR] = 1.24; 95% CI, 1.11-1.37; P < .001), not DTI (HR = 0.92; 95% CI, 0.82-1.03; P = .150) or DTE (HR = 1.01; 95% CI, 0.90-1.15; P = .825), were associated with impaired overall survival. We identified 922 patients who received induction chemotherapy. Delays in DTI, RTD, and DTE were not associated with overall survival in this cohort (HR = 1.10; 95% CI, 0.87-1.39; P = 0.435; HR = 1.05; 95% CI, 0.83-1.32; P = 0.686; HR = 1.11; 95% CI, 0.88-1.41; P = 0.377, respectively). CONCLUSIONS: The median durations identified can serve as national benchmarks. Delays during radiation are associated with impaired overall survival among patients treated with primary radiation or chemoradiation but not patients treated with induction chemotherapy.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Morse E, Berson E, Fujiwara R, et al. Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association. Otolaryngol Head Neck Surg. 2018. PMID: 30324861. doi:10.1177/0194599818797605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。